Akari Therapeutics, Plc Other Current Assets
Akari Therapeutics, Plc (AKTX) had Other Current Assets of $38.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2026-08-13
- 2026-06-30: Other Assets, Current $38.00K.
- 2026-03-31: Other Assets, Current $30.00K.
- 2025-12-31: Other Assets, Current $14.00K.
- 2025-09-30: Other Assets, Current $53.00K.
| Period end | Other Assets, Current | Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $38.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $30.00K 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $14.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $53.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $83.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $80.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $201.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $92.00K 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $94.00K 10-Q · filed 2024-08-19 | |
| 2024-03-31 | $232.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $197.00K 10-K · filed 2025-04-15 | |
| 2023-06-30 | $186.57K 6-K · filed 2023-09-29 | |
| 2022-12-31 | $100.00K 10-K · filed 2024-03-29 | $99.54K 20-F · filed 2023-05-01 |
| 2022-06-30 | $115.17K 6-K · filed 2022-09-27 | |
| 2021-12-31 | $90.30K 20-F · filed 2023-05-01 | |
| 2020-12-31 | $229.20K 20-F · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |